CDK2-IN-13 is a potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), making it a valuable tool in cancer research. It is primarily used to study cell cycle regulation, especially in cancers where CDK2 activity is dysregulated, such as ovarian, breast, and certain leukemias. By inhibiting CDK2, this compound induces cell cycle arrest at the G1/S phase, preventing uncontrolled cell proliferation. It has shown synergistic effects when combined with other anticancer agents, particularly in overcoming resistance to CDK4/6 inhibitors. CDK2-IN-13 is widely used in preclinical studies to validate CDK2 as a therapeutic target and to explore new combination therapies in oncology. Its selectivity helps minimize off-target effects, allowing for more accurate assessment of CDK2's role in tumor growth and survival pathways.